{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:40:38Z","timestamp":1793364038735,"version":"4.5.0"},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Diffuse intrinsic pontine glioma (DIPG) mainly affects children with a median age\nof 6-7 years old. It accounts for 10% of all pediatric tumors. Unfortunately, DIPG has a poor\nprognosis, and the median survival is generally less than 16-24 months independently from\nthe treatment received. Up to now, children with DIPG are treated with focal radiotherapy\nalone or in combination with antitumor agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In the last decade, ONC201 known as dopamine receptor antagonist was uncovered, by a high\nthroughput screening of public libraries of compounds, to be endowed with cytotoxic activity\nagainst several cancer cell lines. Efforts were made to identify the real ONC201 target, responsible\nfor its antiproliferative effect. The hypothesized targets were the Tumor necrosis\nfactor-Related Apoptosis-Inducing Ligand stimulation (TRAIL), two oncogenic kinases\n(ERK\/AKT system) that target the same tumor-suppressor gene (FOXO3a), dopamine receptors\n(DRD2 and DRD3 subtypes) and finally the mitochondrial Caseynolitic Protease P\n(ClpP). ONC201 structure-activity relationship is extensively discussed in this review, together\nwith other two classes of compounds, namely ADEPs and D9, already known for their\nantibiotic activity but noteworthy to be discussed and studied as potential \u201cleads\u201d for the development\nof new drugs to be used in the treatment of DIPG.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this review, a detailed and critical description of ONC201, ADEPs, and D9 pro-apoptotic\nactivity is made, with particular attention to the specific interactions established with its targets\nthat also are intimately described. Pubmed published patents and clinical trial reports of\nthe last ten years were used as the bibliographic source.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200806110206","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T06:17:38Z","timestamp":1596867458000},"page":"3287-3317","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-5228","authenticated-orcid":true,"given":"Maria Grazia","family":"Perrone","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70125 Bari,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3511","authenticated-orcid":true,"given":"Antonio","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3318-2704","authenticated-orcid":true,"given":"Antonella","family":"Centonze","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70125 Bari,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-6667","authenticated-orcid":true,"given":"Antonio","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70125 Bari,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6686-9364","authenticated-orcid":true,"given":"Savina","family":"Ferorelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70125 Bari,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-6425","authenticated-orcid":true,"given":"Antonio","family":"Scilimati","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70125 Bari,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1177\/003591572601900901","author":"Harris W.","unstructured":"Harris W.;  Case of pontine glioma, with special reference to the paths of gustatory sensation Proc. R. Soc. Med., 1926, 19(Neurol Sect), 1-5.","journal-title":"Case of pontine glioma, with special reference to the paths of gustatory sensation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0360-3016(97)00572-5","volume":"40","author":"Freeman C.R.","year":"1998","unstructured":"Freeman C.R.; Farmer J.P.; Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 1998,40(2),265-271","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"Cooney T.","year":"2017","unstructured":"Cooney T.; Lane A.; Bartels U.; Bouffet E.; Goldman S.; Leary S.E.S.; Foreman N.K.; Packer R.J.; Broniscer A.; Minturn J.E.; Shih C.S.; Chintagumpala M.; Hassall T.; Gottardo N.G.; Dholaria H.; Hoffman L.; Chaney B.; Baugh J.; Doughman R.; Leach J.L.; Jones B.V.; Fouladi M.; Warren K.E.; Monje M.; Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro-oncol 2017,19(9),1279-1280","journal-title":"Neuro-oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","volume":"7","author":"Hargrave D.","year":"2006","unstructured":"Hargrave D.; Bartels U.; Bouffet E.; Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006,7(3),241-248","journal-title":"Lancet Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/neuonc\/noy070","volume":"20","author":"Gupta N.","year":"2018","unstructured":"Gupta N.; Goumnerova L.C.; Manley P.; Chi S.N.; Neuberg D.; Puligandla M.; Fangusaro J.; Goldman S.; Tomita T.; Alden T.; DiPatri A.; Rubin J.B.; Gauvain K.; Limbrick D.; Leonard J.; Geyer J.R.; Leary S.; Browd S.; Wang Z.; Sood S.; Bendel A.; Nagib M.; Gardner S.; Karajannis M.A.; Harter D.; Ayyanar K.; Gump W.; Bowers D.C.; Weprin B.; MacDonald T.J.; Aguilera D.; Brahma B.; Robison N.J.; Kiehna E.; Krieger M.; Sandler E.; Aldana P.; Khatib Z.; Ragheb J.; Bhatia S.; Mueller S.; Banerjee A.; Bredlau A-L.; Gururangan S.; Fuchs H.; Cohen K.J.; Jallo G.; Dorris K.; Handler M.; Comito M.; Dias M.; Nazemi K.; Baird L.; Murray J.; Lindeman N.; Hornick J.L.; Malkin H.; Sinai C.; Greenspan L.; Wright K.D.; Prados M.; Bandopadhayay P.; Ligon K.L.; Kieran M.W.; Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-oncol 2018,20(11),1547-1555","journal-title":"Neuro-oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"Schwartzentruber J.","year":"2012","unstructured":"Schwartzentruber J.; Korshunov A.; Liu X-Y.; Jones D.T.W.; Pfaff E.; Jacob K.; Sturm D.; Fontebasso A.M.; Quang D.A.; T&#xF6;njes M.; Hovestadt V.; Albrecht S.; Kool M.; Nantel A.; Konermann C.; Lindroth A.; J&#xE4;ger N.; Rausch T.; Ryzhova M.; Korbel J-O.; Hielscher T.; Hauser P.; Garami M.; Klekner A.; Bognar L.; Ebinger M.; Schuhmann M.U.; Scheurlen W.; Pekrun A.; Fr&#xFC;hwald M.C.; Roggendorf W.; Kramm C.; D&#xFC;rken M.; Atkinson J.; Lepage P.; Montpetit A.; Zakrzewska M.; Zakrzewski K.; Liberski P.P.; Dong Z.; Siegel P.; Kulozik A.E.; Zapatka M.; Guha A.; Malkin D.; Felsberg J.; Reifenberger G.; von Deimling A.; Ichimura K.; Collins V.P.; Witt H.; Milde T.; Witt O.; Zhang C.; Castelo-Branco P.; Lichter P.; Faury D.; Tabori U.; Plass C.; Majewski J.; Pfister S.M.; Jabado N.; Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012,482(7384),226-231","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"Louis D.N.","year":"2016","unstructured":"Louis D.N.; Perry A.; Reifenberger G.; von Deimling A.; Figarella-Branger D.; Cavenee W.K.; Ohgaki H.; Wiestler O.D.; Kleihues P.; Ellison D.W.; The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016,131(6),803-820","journal-title":"Acta Neuropathol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11060-014-1448-8","volume":"119","author":"Robison N.J.","year":"2014","unstructured":"Robison N.J.; Kieran M.W.; Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol 2014,119(1),7-15","journal-title":"J Neurooncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.18632\/oncotarget.1801","volume":"5","author":"Li J.","year":"2014","unstructured":"Li J.; Zhu S.; Kozono D.; Ng K.; Futalan D.; Shen Y.; Akers J.C.; Steed T.; Kushwaha D.; Schlabach M.; Carter B.S.; Kwon C-H.; Furnari F.; Cavenee W.; Elledge S.; Chen C.C.; Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 2014,5(4),882-893","journal-title":"Oncotarget"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00263825","volume":"7","author":"Langmoen I.A.","year":"1991","unstructured":"Langmoen I.A.; Lundar T.; Storm-Mathisen I.; Lie S.O.; Hovind K.H.; Management of pediatric pontine gliomas. Childs Nerv Syst 1991,7(1),13-15","journal-title":"Childs Nerv Syst"},{"key":"ref=11","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/? term = diffuse+intrinsic+pontine+glioma"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004828","volume":"5","author":"Allen J.E.","year":"2013","unstructured":"Allen J.E.; Krigsfeld G.; Mayes P.A.; Patel L.; Dicker D.T.; Patel A.S.; Dolloff N.G.; Messaris E.; Scata K.A.; Wang W.; Zhou J-Y.; Wu G.S.; El-Deiry W.S.; Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013,5(171)","journal-title":"Sci Transl Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/neuonc\/nox210","volume":"20","author":"Caragher S.P.","year":"2018","unstructured":"Caragher S.P.; Hall R.R.; Ahsan R.; Ahmed A.U.; Monoamines in glioblastoma: complex biology with therapeutic potential. Neuro-oncol 2018,20(8),1014-1025","journal-title":"Neuro-oncol"},{"key":"ref=14","author":"Madhukar N.S.","unstructured":"Madhukar N.S.; Elemento O.; Benes C.H.; Garnett M.J.; Stein M.; Bertino J.R.; Kaufman H.L.; Arrillaga-Romany I.; Batchelor T.T.; Schalop L.; Oster W.; Stogniew M.; Andreeff M.; El-Deiry W.S.; Allen J.E.;  Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR)","journal-title":"Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","volume":"14","author":"Allen J.E.","year":"2015","unstructured":"Allen J.E.; Krigsfeld G.; Patel L.; Mayes P.A.; Dicker D.T.; Wu G.S.; El-Deiry W.S.; Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer 2015,14(99),99","journal-title":"Mol Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3892\/ol.2014.1922","volume":"7","author":"Refaat A.","year":"2014","unstructured":"Refaat A.; Abd-Rabou A.; Reda A.; TRAIL combinations: the new \u2018trail\u2019 for cancer therapy.(Review) Oncol Lett 2014,7(5),1327-1332","journal-title":"Oncol Lett"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.32607\/20758251-2017-9-3-55-63","volume":"9","author":"Ukrainskaya V.M.","year":"2017","unstructured":"Ukrainskaya V.M.; Stepanov A.V.; Glagoleva I.S.; Knorre V.D.; Belogurov A.A.; Death receptors: new opportunities in cancer therapy. Acta Naturae 2017,9(3),55-63","journal-title":"Acta Naturae"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/1535370215579167","volume":"240","author":"Dai X.","year":"2015","unstructured":"Dai X.; Zhang J.; Arfuso F.; Chinnathambi A.; Zayed M-E.; Alharbi S.A.; Kumar A.P.; Ahn K.S.; Sethi G.; Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) 2015,240(6),760-773","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"74380","DOI":"10.18632\/oncotarget.11814","volume":"7","author":"Allen J.E.","year":"2016","unstructured":"Allen J.E.; Kline C.L.B.; Prabhu V.V.; Wagner J.; Ishizawa J.; Madhukar N.; Lev A.; Baumeister M.; Zhou L.; Lulla A.; Stogniew M.; Schalop L.; Benes C.; Kaufman H.L.; Pottorf R.S.; Nallaganchu B.R.; Olson G.L.; Al-Mulla F.; Duvic M.; Wu G.S.; Dicker D.T.; Talekar M.K.; Lim B.; Elemento O.; Oster W.; Bertino J.; Flaherty K.; Wang M.L.; Borthakur G.; Andreeff M.; Stein M.; El-Deiry W.S.; Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 2016,7(45),74380-74392","journal-title":"Oncotarget"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"ra18","DOI":"10.1126\/scisignal.aac4374","volume":"9","author":"Kline C.L.B.","year":"2016","unstructured":"Kline C.L.B.; Van den Heuvel A.P.; Allen J.E.; Prabhu V.V.; Dicker D.T.; El-Deiry W.S.; ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2&#x3B1; kinases. Sci Signal 2016,9(415),ra18","journal-title":"Sci Signal"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143082","volume":"10","author":"Allen J.E.","year":"2015","unstructured":"Allen J.E.; Crowder R.N.; El-Deiry W.S.; First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent. PLoS One 2015,10(11)","journal-title":"PLoS One"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"18454","DOI":"10.18632\/oncotarget.24862","volume":"9","author":"Greer Y.E.","year":"2018","unstructured":"Greer Y.E.; Porat-Shliom N.; Nagashima K.; Stuelten C.; Crooks D.; Koparde V.N.; Gilbert S.F.; Islam C.; Ubaldini A.; Ji Y.; Gattinoni L.; Soheilian F.; Wang X.; Hafner M.; Shetty J.; Tran B.; Jailwala P.; Cam M.; Lang M.; Voeller D.; Reinhold W.C.; Rajapakse V.; Pommier Y.; Weigert R.; Linehan W.M.; Lipkowitz S.; ONC201 kills breast cancer cells in vitro by targeting mitochondria. Oncotarget 2018,9(26),18454-18479","journal-title":"Oncotarget"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-17-0121","volume":"16","author":"Ralff M.D.","year":"2017","unstructured":"Ralff M.D.; Kline C.L.B.; K&#xFC;&#xE7;&#xFC;kkase O.C.; Wagner J.; Lim B.; Dicker D.T.; Prabhu V.V.; Oster W.; El-Deiry W.S.; ONC201 demonstrates anti-tumor effects in both triple negative and non-triple negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther 2017,16(7),1290-1298","journal-title":"Mol Cancer Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"ra17","DOI":"10.1126\/scisignal.aac4380","volume":"9","author":"Ishizawa J.","year":"2016","unstructured":"Ishizawa J.; Kojima K.; Chachad D.; Ruvolo P.; Ruvolo V.; Jacamo R.O.; Borthakur G.; Mu H.; Zeng Z.; Tabe Y.; Allen J.E.; Wang Z.; Ma W.; Lee H.C.; Orlowski R.; Sarbassov D.; Lorenzi P.L.; Huang X.; Neelapu S.S.; McDonnell T.; Miranda R.N.; Wang M.; Kantarjian H.; Konopleva M.; Davis R.E.; Andreeff M.; ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 2016,9(415),ra17","journal-title":"Sci Signal"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"21626","DOI":"10.18632\/oncotarget.15451","volume":"8","author":"Yuan X.","year":"2017","unstructured":"Yuan X.; Kho D.; Xu J.; Gajan A.; Wu K.; Wu G.S.; ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget 2017,8(13),21626-21638","journal-title":"Oncotarget"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","volume":"459","author":"Cao Z.","year":"2019","unstructured":"Cao Z.; Liao Q.; Su M.; Huang K.; Jin J.; Cao D.; AKT and ERK dual inhibitors: The way forward? Cancer Lett 2019,459,30-40","journal-title":"Cancer Lett"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","volume":"17","author":"Liu Y.","year":"2018","unstructured":"Liu Y.; Ao X.; Ding W.; Ponnusamy M.; Wu W.; Hao X.; Yu W.; Wang Y.; Li P.; Wang J.; Critical role of FOXO3a in carcinogenesis. Mol Cancer 2018,17(1),104","journal-title":"Mol Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrg2523","volume":"10","author":"Hannenhalli S.","year":"2009","unstructured":"Hannenhalli S.; Kaestner K.H.; The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009,10(4),233-240","journal-title":"Nat Rev Genet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4331\/wjbc.v5.i3.346","volume":"5","author":"Nho R.S.","year":"2014","unstructured":"Nho R.S.; Hergert P.; FoxO3a and disease progression. World J Biol Chem 2014,5(3),346-354","journal-title":"World J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.redox.2015.06.019","volume":"6","author":"Klotz L-O.","year":"2015","unstructured":"Klotz L-O.; S&#xE1;nchez-Ramos C.; Prieto-Arroyo I.; Urb&#xE1;nek P.; Steinbrenner H.; Monsalve M.; Redox regulation of FoxO transcription factors. Redox Biol 2015,6,51-72","journal-title":"Redox Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3892\/ol.2017.5851","volume":"13","author":"Wang X.","year":"2017","unstructured":"Wang X.; Hu S.; Liu L.; Phosphorylation and acetylation modifications of FOXO3a: Independently or synergistically? Oncol Lett 2017,13(5),2867-2872","journal-title":"Oncol Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ncb0208-125","volume":"10","author":"Yang W.","year":"2008","unstructured":"Yang W.; Dolloff N.G.; El-Deiry W.S.; ERK and MDM2 prey on FOXO3a. Nat Cell Biol 2008,10(2),125-126","journal-title":"Nat Cell Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1078-0432.CCR-08-0124","volume":"15","author":"Yang J-Y.","year":"2009","unstructured":"Yang J-Y.; Hung M-C.; A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009,15(3),752-757","journal-title":"Clin Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers11010090","volume":"11","author":"Beretta G.L.","year":"2019","unstructured":"Beretta G.L.; Corno C.; Zaffaroni N.; Perego P.; Role of FoxO proteins in cellular response to antitumor agents. Cancers (Basel) 2019,11(1),90","journal-title":"Cancers (Basel)"},{"key":"ref=35","doi-asserted-by":"publisher","author":"Madhukar N.S.","unstructured":"Madhukar N.S.; Khade P.; Huang L.; Gayvert K.; Galletti G.; Stogniew M.; Allen J.E.; Giannakakou P.; Elemento O.;  O. A new big-data paradigm for target identification and drug discovery. bioRxiv, 2017, 134973. [Preprint paper].","DOI":"10.1101\/134973"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neo.2017.10.002","volume":"20","author":"Kline C.L.B.","year":"2018","unstructured":"Kline C.L.B.; Ralff M.D.; Lulla A.R.; Wagner J.M.; Abbosh P.H.; Dicker D.T.; Allen J.E.; El-Deiry W.S.; Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 2018,20(1),80-91","journal-title":"Neoplasia"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-18-2572","volume":"25","author":"Prabhu V.V.","year":"2019","unstructured":"Prabhu V.V.; Madhukar N.S.; Gilvary C.; Kline C.L.B.; Oster S.; El-Deiry W.S.; Elemento O.; Doherty F.; VanEngelenburg A.; Durrant J.; Tarapore R.S.; Deacon S.; Charter N.; Jung J.; Park D.M.; Gilbert M.R.; Rusert J.; Wechsler-Reya R.; Arrillaga-Romany I.; Batchelor T.T.; Wen P.Y.; Oster W.; Allen J.E.; Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism. Clin Cancer Res 2019,25(7),2305-2313","journal-title":"Clin Cancer Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"832","DOI":"10.12968\/bjon.1998.7.14.5636","volume":"7","author":"Birtwistle J.","year":"1998","unstructured":"Birtwistle J.; Baldwin D.; Role of dopamine in schizophrenia and Parkinson\u2019s disease. Br J Nurs 1998,7(14),832-834, 836, 838-841","journal-title":"Br J Nurs"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.77","volume":"6","author":"Cheng H.W.","year":"2015","unstructured":"Cheng H.W.; Liang Y.H.; Kuo Y.L.; Chuu C.P.; Lin C.Y.; Lee M.H.; Wu A.T.; Yeh C.T.; Chen E.I.; Whang-Peng J.; Su C-L.; Huang C-Y.F.; Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis 2015,6(5)","journal-title":"Cell Death Dis"},{"key":"ref=40","doi-asserted-by":"publisher","author":"Chi A.S.","unstructured":"Chi A.S.; Stafford J.M.; Sen N.; Possemato R.; Placantonakis D.; Hidalgo E.T.; Harter D.; Wisoff J.; Golfinos J.; Arrillaga-Romany I.; Batchelor T.; Wen P.; Wakimoto H.; Cahill D.; Allen J.E.; Oster W.; Snuderl M.;  Exth-42. H3K27M mutant gliomas are selectively killed by ONC201, a small molecule inhibitor of dopamine receptor D2. Neuro-Oncology, 2017, 19(suppl_6), vi81.","DOI":"10.1093\/neuonc\/nox168.334"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","volume":"23","author":"Stein M.N.","year":"2017","unstructured":"Stein M.N.; Bertino J.R.; Kaufman H.L.; Mayer T.; Moss R.; Silk A.; Chan N.; Malhotra J.; Rodriguez L.; Aisner J.; Aiken R.D.; Haffty B.G.; DiPaola R.S.; Saunders T.; Zloza A.; Damare S.; Beckett Y.; Yu B.; Najmi S.; Gabel C.; Dickerson S.; Zheng L.; El-Deiry W.S.; Allen J.E.; Stogniew M.; Oster W.; Mehnert J.M.; First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 2017,23(15),4163-4169","journal-title":"Clin Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","volume":"7","author":"Stein M.N.","year":"2019","unstructured":"Stein M.N.; Malhotra J.; Tarapore R.S.; Malhotra U.; Silk A.W.; Chan N.; Rodriguez L.; Aisner J.; Aiken R.D.; Mayer T.; Haffty B.G.; Newman J.H.; Aspromonte S.M.; Bommareddy P.K.; Estupinian R.; Chesson C.B.; Sadimin E.T.; Li S.; Medina D.J.; Saunders T.; Frankel M.; Kareddula A.; Damare S.; Wesolowsky E.; Gabel C.; El-Deiry W.S.; Prabhu V.V.; Allen J.E.; Stogniew M.; Oster W.; Bertino J.R.; Libutti S.K.; Mehnert J.M.; Zloza A.; Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 2019,7(1),136","journal-title":"J Immunother Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"79298","DOI":"10.18632\/oncotarget.17837","volume":"8","author":"Arrillaga-Romany I.","year":"2017","unstructured":"Arrillaga-Romany I.; Chi A.S.; Allen J.E.; Oster W.; Wen P.Y.; Batchelor T.T.; A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017,8(45),79298-79304","journal-title":"Oncotarget"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2019.2.PEDS18480","volume":"23","author":"Hall M.D.","year":"2019","unstructured":"Hall M.D.; Odia Y.; Allen J.E.; Tarapore R.; Khatib Z.; Niazi T.N.; Daghistani D.; Schalop L.; Chi A.S.; Oster W.; Mehta M.P.; First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr 2019,23(6),1-7","journal-title":"J Neurosurg Pediatr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","volume":"145","author":"Chi A.S.","year":"2019","unstructured":"Chi A.S.; Tarapore R.S.; Hall M.D.; Shonka N.; Gardner S.; Umemura Y.; Sumrall A.; Khatib Z.; Mueller S.; Kline C.; Zaky W.; Khatua S.; Weathers S-P.; Odia Y.; Niazi T.N.; Daghistani D.; Cherrick I.; Korones D.; Karajannis M.A.; Kong X-T.; Minturn J.; Waanders A.; Arillaga-Romany I.; Batchelor T.; Wen P.Y.; Merdinger K.; Schalop L.; Stogniew M.; Allen J.E.; Oster W.; Mehta M.P.; Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019,145(1),97-105","journal-title":"J Neurooncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1124\/jpet.119.256818","volume":"370","author":"Weissenrieder J.S.","year":"2019","unstructured":"Weissenrieder J.S.; Neighbors J.D.; Mailman R.B.; Hohl R.J.; Cancer and the dopamine d2 receptor: a pharmacological perspective. J Pharmacol Exp Ther 2019,370(1),111-126","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature25758","volume":"555","author":"Wang S.","year":"2018","unstructured":"Wang S.; Che T.; Levit A.; Shoichet B.K.; Wacker D.; Roth B.L.; Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 2018,555(7695),269-273","journal-title":"Nature"},{"key":"ref=48","year":"2019","unstructured":"Oncoceutics, ONC201, Briefing Document, Oncologic Drugs Advisory Committee Pediatric Subcommittee,2019 https:\/\/www.fda.gov\/media\/128027\/download"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","volume":"35","author":"Ishizawa J.","year":"2019","unstructured":"Ishizawa J.; Zarabi S.F.; Davis R.E.; Halgas O.; Nii T.; Jitkova Y.; Zhao R.; St-Germain J.; Heese L.E.; Egan G.; Ruvolo V.R.; Barghout S.H.; Nishida Y.; Hurren R.; Ma W.; Gronda M.; Link T.; Wong K.; Mabanglo M.; Kojima K.; Borthakur G.; MacLean N.; Ma M.C.J.; Leber A.B.; Minden M.D.; Houry W.; Kantarjian H.; Stogniew M.; Raught B.; Pai E.F.; Schimmer A.D.; Andreeff M.; Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell 2019,35(5),721-737.e9","journal-title":"Cancer Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ccell.2019.04.010","volume":"35","author":"Wang S.","year":"2019","unstructured":"Wang S.; Dougan D.A.; The direct molecular target for Imipridone ONC201 is finally established. Cancer Cell 2019,35(5),707-708","journal-title":"Cancer Cell"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1021\/acschembio.9b00347","volume":"14","author":"Wong K.S.","year":"2019","unstructured":"Wong K.S.; Houry W.A.; Chemical modulation of human mitochondrial ClpP: potential application in cancer therapeutics. ACS Chem Biol 2019,14(11),2349-2360","journal-title":"ACS Chem Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/pro.3590","volume":"28","author":"Amor A.J.","year":"2019","unstructured":"Amor A.J.; Schmitz K.R.; Baker T.A.; Sauer R.T.; Roles of the ClpX IGF loops in ClpP association, dissociation, and protein degradation. Protein Sci 2019,28(4),756-765","journal-title":"Protein Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2018.07.013","volume":"202","author":"Pustylnikov S.","year":"2018","unstructured":"Pustylnikov S.; Costabile F.; Beghi S.; Facciabene A.; Targeting mitochondria in cancer: current concepts and immunotherapy approaches. Transl Res 2018,202,35-51","journal-title":"Transl Res"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002507","volume":"14","author":"Seo J.H.","year":"2016","unstructured":"Seo J.H.; Rivadeneira D.B.; Caino M.C.; Chae Y.C.; Speicher D.W.; Tang H.Y.; Vaira V.; Bosari S.; Palleschi A.; Rampini P.; Kossenkov A.V.; Languino L.R.; Altieri D.C.; The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis. PLoS Biol 2016,14(7)","journal-title":"PLoS Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-981-13-8367-0_8","author":"Wong K.S.","year":"2019","unstructured":"Wong K.S.; Houry W.A.;  Recent advances in targeting human mitochondrial Mitochondria in Health and in Sickness; Urbani, A 2019,119-142","journal-title":"Recent advances in targeting human mitochondrial Mitochondria in Health and in Sickness; Urbani, A"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/ijms20092232","volume":"20","author":"Moreno-Cinos C.","year":"2019","unstructured":"Moreno-Cinos C.; Goossens K.; Salado I.G.; Van Der Veken P.; De Winter H.; Augustyns K.; Clp P.; ClpP protease, a promising antimicrobial target. Int J Mol Sci 2019,20(9),2232","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.bmc.2011.07.047","volume":"20","author":"Zeiler E.","year":"2012","unstructured":"Zeiler E.; Korotkov V.S.; Lorenz-Baath K.; B&#xF6;ttcher T.; Sieber S.A.; Development and characterization of improved &#x3B2;-lactone-based anti-virulence drugs targeting ClpP. Bioorg Med Chem 2012,20(2),583-591","journal-title":"Bioorg Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/nm1306","volume":"11","author":"Br&#xF6;tz-Oesterhelt H.","year":"2005","unstructured":"Br&#xF6;tz-Oesterhelt H.; Beyer D.; Kroll H.P.; Endermann R.; Ladel C.; Schroeder W.; Hinzen B.; Raddatz S.; Paulsen H.; Henninger K.; Bandow J.E.; Sahl H-G.; Labischinski H.; Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med 2005,11(10),1082-1087","journal-title":"Nat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1039\/C6MB00644B","volume":"13","author":"Ye F.","year":"2016","unstructured":"Ye F.; Li J.; Yang C.G.; The development of small-molecule modulators for ClpP protease activity. Mol Biosyst 2016,13(1),23-31","journal-title":"Mol Biosyst"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.1016\/j.bmc.2010.08.032","volume":"18","author":"Socha A.M.","year":"2010","unstructured":"Socha A.M.; Tan N.Y.; LaPlante K.L.; Sello J.K.; Diversity-oriented synthesis of cyclic acyldepsipeptides leads to the discovery of a potent antibacterial agent. Bioorg Med Chem 2010,18(20),7193-7202","journal-title":"Bioorg Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"14602","DOI":"10.1002\/anie.201808189","volume":"57","author":"Stahl M.","year":"2018","unstructured":"Stahl M.; Korotkov V.S.; Balogh D.; Kick L.M.; Gersch M.; Pahl A.; Kielkowski P.; Richter K.; Schneider S.; Sieber S.A.; Selective activation of human caseinolytic protease P (ClpP). Angew Chem Int Ed Engl 2018,57(44),14602-14607","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=62","doi-asserted-by":"publisher","author":"Stein M.N.","unstructured":"Stein M.N.; Mayer T.M.; Moss R.A.; Silk A.W.; Chan N.; Haffty B.G.; DiPaola R.S.; Beckett Y.; Bentlyewski E.; Zheng L.; Fang B.; Allen J.E.; Mehnert J.M.;  First-inhuman dose escalation study of oral ONC201 in advanced solid tumors. J. Clin. Oncol., 2015, 33(15_suppl), TPS2623-TPS2623.","DOI":"10.1200\/jco.2015.33.15_suppl.tps2623"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/acschembio.9b00222","volume":"14","author":"Graves P.R.","year":"2019","unstructured":"Graves P.R.; Aponte-Collazo L.J.; Fennell E.M.J.; Graves A.C.; Hale A.E.; Dicheva N.; Herring L.E.; Gilbert T.S.K.; East M.P.; McDonald I.M.; Lockett M.R.; Ashamalla H.; Moorman N.J.; Karanewsky D.S.; Iwanowicz E.J.; Holmuhamedov E.; Graves L.M.; Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chem Biol 2019,14(5),1020-1029","journal-title":"ACS Chem Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1080\/15384101.2017.1325046","volume":"16","author":"Wagner J.","year":"2017","unstructured":"Wagner J.; Kline C.L.; Ralff M.D.; Lev A.; Lulla A.; Zhou L.; Olson G.L.; Nallaganchu B.R.; Benes C.H.; Allen J.E.; Prabhu V.V.; Stogniew M.; Oster W.; El-Deiry W.S.; Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle 2017,16(19),1790-1799","journal-title":"Cell Cycle"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.1002\/anie.201402133","volume":"53","author":"Jacob N.T.","year":"2014","unstructured":"Jacob N.T.; Lockner J.W.; Kravchenko V.V.; Janda K.D.; Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl 2014,53(26),6628-6631","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1021\/acsmedchemlett.8b00531","volume":"10","author":"Ma Z.","year":"2019","unstructured":"Ma Z.; Gao G.; Fang K.; Sun H.; Development of novel anticancer agents with a scaffold of tetrahydropyrido[4,3-d]pyrimidine-2,4-dione. ACS Med Chem Lett 2019,10(2),191-195","journal-title":"ACS Med Chem Lett"},{"key":"ref=67","author":"Xu R.L.Y.","year":"2016","unstructured":"Xu R.L.Y.;  Imidazo-pyrimidine compounds, and preparation methods and application thereofInternational Patent WO2016\/184437 2016","journal-title":"Imidazo-pyrimidine compounds, and preparation methods and application thereofInternational Patent WO2016\/184437"},{"key":"ref=68","author":"Iwanowicz E.J.","year":"2018","unstructured":"Iwanowicz E.J.;  Protein kinase regulatorsInternational\tPatent WO2018\/0319872018, 2018","journal-title":"Protein kinase regulatorsInternational\tPatent WO2018\/0319872018,"},{"key":"ref=69","author":"Iwanowicz E.J.","year":"2018","unstructured":"Iwanowicz E.J.;  Protein kinase regulators International\tPatent WO2018\/031990A1 2018","journal-title":"Protein kinase regulators International\tPatent WO2018\/031990A1"},{"key":"ref=70","author":"Allen J.E.","year":"2020","unstructured":"Allen J.E.; Prabhu V.V.; Stogniew M.;  Imipridones for Gliomas USPatent US2020\/0022982 2020","journal-title":"Imipridones for Gliomas USPatent US2020\/0022982"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jsb.2004.07.004","volume":"148","author":"Kang S.G.","year":"2004","unstructured":"Kang S.G.; Maurizi M.R.; Thompson M.; Mueser T.; Ahvazi B.; Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP. J Struct Biol 2004,148(3),338-352","journal-title":"J Struct Biol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.chembiol.2018.05.014","volume":"25","author":"Wong K.S.","year":"2018","unstructured":"Wong K.S.; Mabanglo M.F.; Seraphim T.V.; Mollica A.; Mao Y.Q.; Rizzolo K.; Leung E.; Moutaoufik M.T.; Hoell L.; Phanse S.; Goodreid J.; Barbosa L.R.S.; Ramos C.H.I.; Babu M.; Mennella V.; Batey R.A.; Schimmer A.D.; Houry W.A.; Acyldepsipeptide analogs dysregulate human mitochondrial ClpP protease activity and cause apoptotic cell death. Cell Chem Biol 2018,25(8),1017-1030.e9","journal-title":"Cell Chem Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1148\/122.2.463","volume":"122","author":"Greenberger J.S.","year":"1977","unstructured":"Greenberger J.S.; Cassady J.R.; Levene M.B.; Radiation therapy of thalamic, midbrain and brain stem gliomas. Radiology 1977,122(2),463-468","journal-title":"Radiology"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0360-3016(85)90244-5","volume":"11","author":"Halperin E.C.","year":"1985","unstructured":"Halperin E.C.; Pediatric brain stem tumors: patterns of treatment failure and their implications for radiotherapy. Int J Radiat Oncol Biol Phys 1985,11(7),1293-1298","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/1097-0142(19940915)74:6<1827:AID-CNCR2820740628>3.0.CO;2-Q","volume":"74","author":"Packer R.J.","year":"1994","unstructured":"Packer R.J.; Boyett J.M.; Zimmerman R.A.; Albright A.L.; Kaplan A.M.; Rorke L.B.; Selch M.T.; Cherlow J.M.; Finlay J.L.; Wara W.M.; Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I\/II Trial. Cancer 1994,74(6),1827-1834","journal-title":"Cancer"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2014.01.013","volume":"111","author":"Zaghloul M.S.","year":"2014","unstructured":"Zaghloul M.S.; Eldebawy E.; Ahmed S.; Mousa A.G.; Amin A.; Refaat A.; Zaky I.; Elkhateeb N.; Sabry M.; Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 2014,111(1),35-40","journal-title":"Radiother Oncol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.12.007","volume":"73","author":"Janssens G.O.","year":"2017","unstructured":"Janssens G.O.; Gandola L.; Bolle S.; Mandeville H.; Ramos-Albiac M.; van Beek K.; Benghiat H.; Hoeben B.; Morales La Madrid A.; Kortmann R.D.; Hargrave D.; Menten J.; Pecori E.; Biassoni V.; von Bueren A.O.; van Vuurden D.G.; Massimino M.; Sturm D.; Peters M.; Kramm C.M.; Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG\/DIPG working group. Eur J Cancer 2017,73,38-47","journal-title":"Eur J Cancer"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26988","volume":"65","author":"Lassaletta A.","year":"2018","unstructured":"Lassaletta A.; Strother D.; Laperriere N.; Hukin J.; Vanan M.I.; Goddard K.; Lafay-Cousin L.; Johnston D.L.; Zelcer S.; Zapotocky M.; Rajagopal R.; Ramaswamy V.; Hawkins C.; Tabori U.; Huang A.; Bartels U.; Bouffet E.; Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer 2018,65(6)","journal-title":"Pediatr Blood Cancer"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0360-3016(00)00471-5","volume":"47","author":"Freeman C.R.","year":"2000","unstructured":"Freeman C.R.; Kepner J.; Kun L.E.; Sanford R.A.; Kadota R.; Mandell L.; Friedman H.; A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 2000,47(3),561-564","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26832","volume":"65","author":"Kilburn L.B.","year":"2018","unstructured":"Kilburn L.B.; Kocak M.; Baxter P.; Poussaint T.Y.; Paulino A.C.; McIntyre C.; Lemenuel-Diot A.; Lopez-Diaz C.; Kun L.; Chintagumpala M.; Su J.M.; Broniscer A.; Baker J.N.; Hwang E.I.; Fouladi M.; Boyett J.M.; Blaney S.M.; A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer , 10.1002\/pbc.26832.2018,65(2)","journal-title":"Pediatr Blood Cancer"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/neuonc\/noq205","volume":"13","author":"Cohen K.J.","year":"2011","unstructured":"Cohen K.J.; Heideman R.L.; Zhou T.; Holmes E.J.; Lavey R.S.; Bouffet E.; Pollack I.F.; Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group. Neuro-oncol 2011,13(4),410-416","journal-title":"Neuro-oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","volume":"106","author":"Chassot A.","year":"2012","unstructured":"Chassot A.; Canale S.; Varlet P.; Puget S.; Roujeau T.; Negretti L.; Dhermain F.; Rialland X.; Raquin M.A.; Grill J.; Dufour C.; Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 2012,106(2),399-407","journal-title":"J Neurooncol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1179\/1973947814Y.0000000228","volume":"27","author":"Rizzo D.","year":"2015","unstructured":"Rizzo D.; Scalzone M.; Ruggiero A.; Maurizi P.; Attin&#xE0; G.; Mastrangelo S.; Lazzareschi I.; Ridola V.; Colosimo C.; Caldarelli M.; Balducci M.; Riccardi R.; Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother 2015,27(2),106-110","journal-title":"J Chemother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/neuonc\/noq202","volume":"13","author":"Haas-Kogan D.A.","year":"2011","unstructured":"Haas-Kogan D.A.; Banerjee A.; Poussaint T.Y.; Kocak M.; Prados M.D.; Geyer J.R.; Fouladi M.; Broniscer A.; Minturn J.E.; Pollack I.F.; Packer R.J.; Boyett J.M.; Kun L.E.; Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro-oncol 2011,13(3),298-306","journal-title":"Neuro-oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1215\/15228517-2006-031","volume":"9","author":"Pollack I.F.","year":"2007","unstructured":"Pollack I.F.; Jakacki R.I.; Blaney S.M.; Hancock M.L.; Kieran M.W.; Phillips P.; Kun L.E.; Friedman H.; Packer R.; Banerjee A.; Geyer J.R.; Goldman S.; Poussaint T.Y.; Krasin M.J.; Wang Y.; Hayes M.; Murgo A.; Weiner S.; Boyett J.M.; Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-oncol 2007,9(2),145-160","journal-title":"Neuro-oncol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/jns.1987.66.2.0227","volume":"66","author":"Jenkin R.D.","year":"1987","unstructured":"Jenkin R.D.; Boesel C.; Ertel I.; Evans A.; Hittle R.; Ortega J.; Sposto R.; Wara W.; Wilson C.; Anderson J.; Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg 1987,66(2),227-233","journal-title":"J Neurosurg"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2002.04.109","volume":"20","author":"Jennings M.T.","year":"2002","unstructured":"Jennings M.T.; Sposto R.; Boyett J.M.; Vezina L.G.; Holmes E.; Berger M.S.; Bruggers C.S.; Bruner J.M.; Chan K.W.; Dusenbery K.E.; Ettinger L.J.; Fitz C.R.; Lafond D.; Mandelbaum D.E.; Massey V.; McGuire W.; McNeely L.; Moulton T.; Pollack I.F.; Shen V.; Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children\u2019s Cancer Group. J Clin Oncol 2002,20(16),3431-3437","journal-title":"J Clin Oncol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11060-013-1145-z","volume":"113","author":"Ruggiero A.","year":"2013","unstructured":"Ruggiero A.; Rizzo D.; Attin&#xE0; G.; Lazzareschi I.; Maurizi P.; Ridola V.; Mastrangelo S.; Migliorati R.; Bertolini P.; Colosimo C.; Riccardi R.; Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors. J Neurooncol 2013,113(3),513-518","journal-title":"J Neurooncol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","volume":"38","author":"Jansen M.H.","year":"2012","unstructured":"Jansen M.H.; van Vuurden D.G.; Vandertop W.P.; Kaspers G.J.; Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 2012,38(1),27-35","journal-title":"Cancer Treat Rev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00381-014-2568-3","volume":"31","author":"Ho S.L.","year":"2015","unstructured":"Ho S.L.; Singh R.; Zhou Z.; Lavi E.; Souweidane M.M.; Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in na&#xEF;ve rat brainstem. Childs Nerv Syst 2015,31(2),221-226","journal-title":"Childs Nerv Syst"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-09-0996","volume":"9","author":"Luther N.","year":"2010","unstructured":"Luther N.; Cheung N.K.; Souliopoulos E.P.; Karampelas I.; Bassiri D.; Edgar M.A.; Guo H.F.; Pastan I.; Gutin P.H.; Souweidane M.M.; Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther 2010,9(4),1039-1046","journal-title":"Mol Cancer Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1023\/B:NEON.0000024219.47447.91","volume":"67","author":"Souweidane M.M.","year":"2004","unstructured":"Souweidane M.M.; Occhiogrosso G.; Mark E.B.; Edgar M.A.; Interstitial infusion of IL13-PE38QQR in the rat brain stem. J Neurooncol 2004,67(3),287-293","journal-title":"J Neurooncol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"Grasso C.S.","year":"2015","unstructured":"Grasso C.S.; Tang Y.; Truffaux N.; Berlow N.E.; Liu L.; Debily M.A.; Quist M.J.; Davis L.E.; Huang E.C.; Woo P.J.; Ponnuswami A.; Chen S.; Johung T.B.; Sun W.; Kogiso M.; Du Y.; Qi L.; Huang Y.; H&#xFC;tt-Cabezas M.; Warren K.E.; Le Dret L.; Meltzer P.S.; Mao H.; Quezado M.; van Vuurden D.G.; Abraham J.; Fouladi M.; Svalina M.N.; Wang N.; Hawkins C.; Nazarian J.; Alonso M.M.; Raabe E.H.; Hulleman E.; Spellman P.T.; Li X.N.; Keller C.; Pal R.; Grill J.; Monje M.; Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 2015,21(6),555-559","journal-title":"Nat Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/neuonc\/noq199","volume":"13","author":"Pollack I.F.","year":"2011","unstructured":"Pollack I.F.; Stewart C.F.; Kocak M.; Poussaint T.Y.; Broniscer A.; Banerjee A.; Douglas J.G.; Kun L.E.; Boyett J.M.; Geyer J.R.; A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro-oncol 2011,13(3),290-297","journal-title":"Neuro-oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/medicines7050029","volume":"7","author":"Van Gool S.W.","year":"2020","unstructured":"Van Gool S.W.; Makalowski J.; Bonner E.R.; Feyen O.; Domogalla M.P.; Prix L.; Schirrmacher V.; Nazarian J.; Stuecker W.; Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience. Medicines (Basel) 2020,7(5),29-45","journal-title":"Medicines (Basel)"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","volume":"63","author":"Ensan D.","year":"2020","unstructured":"Ensan D.; Smil D.; Zepeda-Vel&#xE1;zquez C.A.; Panagopoulos D.; Wong J.F.; Williams E.P.; Adamson R.; Bullock A.N.; Kiyota T.; Aman A.; Roberts O.G.; Edwards A.M.; O\u2019Meara J.A.; Isaac M.B.; Al-Awar R.; Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma. J Med Chem 2020,63(9),4978-4996","journal-title":"J Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/neuonc\/noaa058]","volume":"22","author":"Bailey C.P.","year":"2020","unstructured":"Bailey C.P.; Figueroa M.; Gangadharan A.; Yang Y.; Romero M.M.; Kennis B.A.; Yadavilli S.; Henry V.; Collier T.; Monje M.; Lee D.A.; Wang L.; Nazarian J.; Gopalakrishnan V.; Zaky W.; Becher O.J.; Chandra J.; Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG). Neuro-oncol 2020,22(9),1302-1314","journal-title":"Neuro-oncol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"S1239","DOI":"10.21037\/tcr.2017.10.03","volume":"6","author":"Ralff M.D.","year":"2017","unstructured":"Ralff M.D.; Lulla A.R.; Wagner J.; El-Deiry W.S.; ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Transl Cancer Res 2017,6(Suppl. 7),S1239-S1243","journal-title":"Transl Cancer Res"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200806110206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184590\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200806110206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T13:55:27Z","timestamp":1654437327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184590\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":98,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200806110206","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}